MX2016011862A - Inhibidores de c5a para el tratamiento de la neumonia viral. - Google Patents

Inhibidores de c5a para el tratamiento de la neumonia viral.

Info

Publication number
MX2016011862A
MX2016011862A MX2016011862A MX2016011862A MX2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A
Authority
MX
Mexico
Prior art keywords
treatment
pneumonia
inhibitors
viral pneumonia
relates
Prior art date
Application number
MX2016011862A
Other languages
English (en)
Inventor
Guo Renfeng
Christoph Riedemann Niels
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50342223&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016011862(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of MX2016011862A publication Critical patent/MX2016011862A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a inhibidores de C5a para uso en el tratamiento de la neumonía, especialmente de la neumonía viral. La invención también se refiere al uso de inhibidores de C5a en la preparación de una composición farmacéutica para el tratamiento de la neumonía, especialmente de la neumonía viral. Los inventores se refieren además a métodos para el tratamiento de la neumonía, especialmente de la neumonía viral, que comprenden la etapa de administrar una cantidad terapéutica de un inhibidor de C5a a un sujeto en necesidad del mismo.
MX2016011862A 2014-03-20 2015-03-20 Inhibidores de c5a para el tratamiento de la neumonia viral. MX2016011862A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14160947 2014-03-20
PCT/EP2015/055947 WO2015140304A1 (en) 2014-03-20 2015-03-20 Inhibitors of c5a for the treatment of viral pneumonia

Publications (1)

Publication Number Publication Date
MX2016011862A true MX2016011862A (es) 2016-12-05

Family

ID=50342223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011862A MX2016011862A (es) 2014-03-20 2015-03-20 Inhibidores de c5a para el tratamiento de la neumonia viral.

Country Status (15)

Country Link
US (2) US10227397B2 (es)
EP (1) EP3119802B1 (es)
JP (2) JP6718379B2 (es)
KR (1) KR20160127042A (es)
CN (2) CN106132982A (es)
AU (1) AU2015233380A1 (es)
BR (1) BR112016021629A2 (es)
CA (1) CA2940319A1 (es)
CL (1) CL2016002255A1 (es)
EA (1) EA201691481A1 (es)
IL (1) IL247364A0 (es)
MX (1) MX2016011862A (es)
PH (1) PH12016501830A1 (es)
SG (1) SG11201607740TA (es)
WO (1) WO2015140304A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160127042A (ko) 2014-03-20 2016-11-02 인플라알엑스 게엠베하 바이러스성 폐렴의 치료를 위한 c5a의 억제제
WO2015143380A1 (en) 2014-03-20 2015-09-24 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
CA3241273A1 (en) 2014-06-12 2015-12-17 Ra Pharmaceuticals, Inc. Modulation of complement activity
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP4218790A1 (en) 2015-12-16 2023-08-02 Ra Pharmaceuticals, Inc. Modulators of complement activity
US20190127453A1 (en) 2016-06-07 2019-05-02 Novartis Ag An anti-c5 antibody dosing regimen
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
TWI826364B (zh) * 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
CA3066689C (en) 2017-06-23 2024-01-16 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
KR20220047826A (ko) 2019-08-16 2022-04-19 리제너론 파마슈티칼스 인코포레이티드 고 농도의 항-c5 제형
US20230158060A1 (en) 2020-03-27 2023-05-25 Inflarx Gmbh Inhibitors of C5a for the Treatment of Corona Virus Infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001301A (es) * 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
ES2561828T3 (es) * 2002-01-25 2016-03-01 Novo Nordisk A/S Anticuerpos monoclonales contra bucles extracelulares de C5aR
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
PL2521562T3 (pl) * 2010-01-08 2020-04-30 Volution Immuno Pharmaceuticals Sa Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
CA2797856C (en) * 2010-04-30 2018-09-18 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies
JP6050747B2 (ja) * 2010-06-17 2016-12-21 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザ受動免疫化に有用な抗体
KR20160127042A (ko) 2014-03-20 2016-11-02 인플라알엑스 게엠베하 바이러스성 폐렴의 치료를 위한 c5a의 억제제

Also Published As

Publication number Publication date
CN116785426A (zh) 2023-09-22
PH12016501830A1 (en) 2016-11-21
AU2015233380A1 (en) 2016-09-08
BR112016021629A2 (pt) 2018-07-10
US10227397B2 (en) 2019-03-12
EA201691481A1 (ru) 2017-02-28
JP2017514791A (ja) 2017-06-08
JP6718379B2 (ja) 2020-07-08
EP3119802A1 (en) 2017-01-25
JP2020125324A (ja) 2020-08-20
SG11201607740TA (en) 2016-10-28
US20170137499A1 (en) 2017-05-18
JP7041708B2 (ja) 2022-03-24
EP3119802B1 (en) 2019-12-04
US20190202900A1 (en) 2019-07-04
IL247364A0 (en) 2016-11-30
CA2940319A1 (en) 2015-09-24
KR20160127042A (ko) 2016-11-02
US10858421B2 (en) 2020-12-08
CL2016002255A1 (es) 2017-08-25
CN106132982A (zh) 2016-11-16
WO2015140304A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX2023008686A (es) Polinucleotidos moduladores.
TW201613901A (en) New compounds
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MY187540A (en) Compounds active towards bromodomains
PH12016500094A1 (en) Autotaxin inhibitors
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
IN2014MU00303A (es)
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
IN2014CH00840A (es)
IN2014MU00916A (es)
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
IN2014CH01391A (es)
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
MX2017001512A (es) Compuestos activos hacia bromodominios.